Somatostatin receptor imaging and therapy of pancreatic endocrine tumors

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Van Eijck, Casper H J ^a   De Jong, M ^a   Breeman, W A P ^a   Slooter, G D ^a   Marquet, R L ^a   Krenning, E P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Pancreatic endocrine tumors; Radionuclide therapy; Somatostatin analogues; Somatostatin receptor scintigraphy

Indexed keywords

PENTETIC ACID DERIVATIVE; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; YTTRIUM 90;

CONFERENCE PAPER; DRUG EFFICACY; ENDOCRINE TUMOR; HORMONE RECEPTOR INTERACTION; HUMAN; LIVER METASTASIS; NONHUMAN; PANCREAS SCINTISCANNING; PANCREAS TUMOR; PRIORITY JOURNAL; TUMOR SCINTISCANNING;

EID: 0032784270     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S177     Document Type: Conference Paper

References (48)

1. Brazeau P, Vale W, Burgus R et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179 (68):77-9.
2. Lucey MR. Endogenous somatostatin and the gut. Gut 1986;27(4):457-67.
3. Reichlin S. Somatostatin (second of two parts). N.Engl.J.Med. 1983;309(25):1556-63.
4. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors., Endocr.Rev. 1991;12(4):450-82.
5. Schally AV. Oncological applications of somatostatin analogues. Cancer Res. 1988;48(24 Pt 1):6977-85.
6. Kvols LK, Moertel CG, O'Connell MJ et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N.Engl.J.Med. 1986; 315 (11):663-6.
7. Reubi JC, Kvols LK, Waser B et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50(18):5969-77.
8. Reubi JC, Lamberts SW, Maurer R. Somatostatin receptors in normal and tumoral tissue. Horm.Res. 1988;29(2-3):65-9.
9. Papotti M, Macri L, Bussolati G, Reubi JC. Correlative study on neuroendocrine differentiation and presence of somatostatin receptors in breast carcinomas. Int.J.Cancer 1989;43(3):365-9.
10. Kubota A, Yamada Y, Kagimoto S et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J.Clin. Invest. 1994;93:1321-5.
11. Amherdt M, Patel YC, Orci L. Selective binding of somatostatin-14 and somatostatin-28 to islet cells revealed by quantitative electron microscopic autoradiography. J.Clin.Invest. 1987;80(5):1455-8.
12. Lamberts SW, Holland LJ, van Koetsveld PM et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J.Clin.Endocrinol.Metab. 1990;71(3): 566-74.
13. Yamada Y, Reisine T, Law SF et al. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol.Endocrinol. 1992;6(12):2136-42.
14. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J.Steroid Biochem.Mol.Biol. 1992;43(1-3):27-35.
15. Reubi JC, Horisberger U, Essed CE et al. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 1988;95(3):760-3.
16. Krenning EP, Bakker WH, Breeman WA et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1(8632):242-4.
17. Krenning EP, Kwekkeboom DJ, Pauwels S et al. Somatostatin receptor scintigraphy. Nucl Med Ann 1995;1-50.
18. Valkema R, Steens J, Cleton FJ, Pauwels EK. The diagnostic utility of somatostatin receptor scintigraphy in oncology. J. Cancer Res. Clin. Oncol. 1996;122(9):513-32.
19. Gibril F, Reynolds JC, Doppman JL et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study Ann.Intern.Med. 1996;125(1):26-34.
20. Cadiot G, Lebtahi R, Sarda L et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. Gastroenterology 1996;111(4):845-54.
21. Le Guludec D, Cadiot G, Lebtahi R, Mignon M. Detection of endocrine tumors of the digestive tract. Value and limitations of scintigraphy of somatostatin receptors. Presse Med. 1996;25(14):677-82.
22. Lebtahi R, Cadiot G, Sarda L et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J.Nucl.Med. 1997;38(6):853-8.
23. Ahlman H. Radioisotope-guided surgery in patients with neuroendocrine tumours. Digestion 1996;57 Suppl 1:88-9.
24. Lamberts SW, Krenning EP, Klijn JG, Reubi JC. The clinical use of somatostatin analogues in the treatment of cancer. Baillieres.Clin.Endocrinol.Metab. 1990;4(1):29-49.
25. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68(2):227-32.
26. van Eyck CH, Bruining HA, Reubi JC et al. Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors. World J.Surg 1993;17(4):444-7.
27. Oberg K, Eriksson B. Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol. 1989;28(3):425-31.
28. Oberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr.Opin.Oncol. 1998;10(1):58-65.
29. Eriksson B, Oberg K, Skogseid B. Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol. 1989;28(3):373-7.
30. Adelstein SJ. Merrill C. Sosman Lecture. The Auger process: a therapeutic promise? AJR.Am.J.Roentgenol. 1993;160(4):707-13.
31. Duncan JR, Behr TM, DeNardo SJ. Intracellular fate of radiometals. J Nucl Med 1997;38(5):829
32. Krenning EP, Kooij PP, Bakker WH et al. Radiotherapy with a radiolabeled Somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N.Y.Acad.Sci. 1994;733:496-506.
33. Slooter GD, Breeman WA, Marquet RL et al. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer 1999;(in press).
34. van Eijck CH, Slooter GD, Hofland LJ et al. Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide. Br J Surg 1994;81:1333-7.
35. Stolz B, Smith-Jones P, Albert R et al. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion 1996;57Suppl 1:17-21.
36. Stolz B, Weckbecker G, Smith-Jones PM et al. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur.J Nucl Med 1998;25(7):668-74.
37. Zamora PO, Gulhke S, Bender H et al. Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer 1996;65(2):214-20.
38. de Jong M, Breeman WA, Bakker WH et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58(3): 437-41.
39. Reubi JC. In vitro identification of VIP receptors in human tumors: potential clinical implications. Ann N.Y.Acad.Sci. 1996;805:753-9.
40. Virgolini I, Raderer M, Kurtaran A et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N.Engl.J Med 1994;331(17):1116-21.
41. Raderer M, Kurtaran A, Yang Q et al. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. 1998;39(9):1570-5.
42. van Hagen PM, Breeman WA, Reubi JC et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur.J Nucl Med 1996;23:1508-13.
43. Hennig IM, Laissue JA, Horisberger U et al. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995;61(6):786-92.
44. Breeman WA, Holland LJ, de Jong M et al. Evaluation of radiolabelled bombesin analogues for receptor- targeted scintigraphy and radiotherapy. Int J Cancer 1999;(In press)
45. Otte A, Jermann E, Behe M et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur.J Nucl Med 1997;24(7):792-5.
46. Otte A, Mueller-Brand J, Dellas S et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment Lancet 1998:351(9100):417-8.
47. de Jong M, Rolleman EJ, Bernard BF et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37(8):1388-92.
48. Bernard BF, Krenning EP, Breeman WA et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38(12):1929-33.